Evotec SE (ETR:EVT)

Market Cap	1.01B
Revenue (ttm)	777.33M
Net Income (ttm)	-155.53M
Shares Out	177.60M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	963,254
Average Volume	951,334
Open	5.84
Previous Close	5.86
Day's Range	5.70 - 5.86
52-Week Range	5.06 - 10.62
Beta	1.06
RSI	33.72
Earnings Date	Aug 13, 2025

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,740
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EVT

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.